Seattle Genetics, Inc. (NASDAQ:SGEN) EVP Darren S. Cline sold 4,167 shares of the business’s stock in a transaction that occurred on Wednesday, November 21st. The stock was sold at an average price of $56.68, for a total value of $236,185.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Darren S. Cline also recently made the following trade(s):
- On Monday, August 27th, Darren S. Cline sold 4,784 shares of Seattle Genetics stock. The stock was sold at an average price of $74.23, for a total value of $355,116.32.
Shares of SGEN opened at $57.24 on Friday. The firm has a market capitalization of $9.17 billion, a price-to-earnings ratio of -65.05 and a beta of 2.18. Seattle Genetics, Inc. has a fifty-two week low of $47.75 and a fifty-two week high of $84.37.
Several research analysts recently issued reports on SGEN shares. Cann restated a “hold” rating on shares of Seattle Genetics in a research report on Monday, October 22nd. Piper Jaffray Companies restated a “neutral” rating on shares of Seattle Genetics in a research report on Friday, September 7th. Guggenheim started coverage on Seattle Genetics in a research report on Monday, September 17th. They set a “buy” rating for the company. Leerink Swann started coverage on Seattle Genetics in a research report on Monday, September 24th. They set an “outperform” rating and a $101.00 price objective for the company. Finally, Zacks Investment Research upgraded Seattle Genetics from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a research report on Thursday, August 23rd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $77.77.
A number of institutional investors and hedge funds have recently modified their holdings of SGEN. Capital International Investors raised its holdings in Seattle Genetics by 53.6% in the 3rd quarter. Capital International Investors now owns 9,414,375 shares of the biotechnology company’s stock valued at $726,037,000 after acquiring an additional 3,285,237 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in Seattle Genetics by 3.0% in the 2nd quarter. Baker BROS. Advisors LP now owns 51,046,060 shares of the biotechnology company’s stock valued at $3,388,948,000 after acquiring an additional 1,470,651 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Seattle Genetics in the 2nd quarter valued at $83,840,000. First Trust Advisors LP raised its holdings in Seattle Genetics by 70.7% in the 3rd quarter. First Trust Advisors LP now owns 1,779,195 shares of the biotechnology company’s stock valued at $137,212,000 after acquiring an additional 736,621 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in Seattle Genetics in the 2nd quarter valued at $37,747,000.
ILLEGAL ACTIVITY NOTICE: “Darren S. Cline Sells 4,167 Shares of Seattle Genetics, Inc. (SGEN) Stock” was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.wkrb13.com/2018/11/23/darren-s-cline-sells-4167-shares-of-seattle-genetics-inc-sgen-stock.html.
Seattle Genetics Company Profile
Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.
Recommended Story: Why do companies engage in swaps?
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.